Connect with us

Hi, what are you looking for?

Stock

US sues to block UnitedHealth’s $3.3 billion purchase of Amedisys

(Reuters) -The U.S. Department of Justice and three U.S. states filed a lawsuit on Tuesday to block UnitedHealth Group (NYSE:UNH)’s $3.3 billion acquisition of Amedisys Inc (NASDAQ:AMED), citing concerns that the deal would reduce competition in the home health services market.

“Eliminating the competition between UnitedHealth and Amedisys would harm patients who receive home health and hospice services, insurers who contract for home health services, and nurses who provide home health and hospice services,” the DOJ said in a statement.

The attorneys generals of Maryland, New Jersey and New York are also suing to block the merger.

The Amedisys combination with Optum would be pro-competitive and further innovation, a spokesperson for Optum said. “We will vigorously defend against the DOJ’s overreaching interpretation of the antitrust laws.”  

UnitedHealth operates Optum, a health services unit that provides analytics, research and pharmacy care services among others. 

A spokesperson for Amedisys said the company remains committed to the transaction. “We look forward to supporting Optum in presenting our case,” the company said.

Following the news, UnitedHealth’s shares fell 1.1% in afternoon trading. Amedisys’ stock was down 2.1% at $90.75 in afternoon trading and is now 10% below UnitedHealth’s offer price of $101 per share.

UnitedHealth announced its intention to acquire Amedisys last year, but analysts anticipated regulatory scrutiny due to UnitedHealth’s presence in the home health sector.

The move follows a recent meeting between the companies’ executives and the DOJ aimed at addressing these concerns, according to Bloomberg News, which first reported the story on Tuesday.

To mitigate antitrust issues, Amedisys proposed selling over 100 locations to a private operator in Texas, contingent upon the deal’s completion, Stephens analyst Scott Fidel said.

“These remedies do not seem sufficient to satisfy the hardline Biden DOJ … Clearly, we’ll look to see whether a Trump DOJ decides to pursue or drop this case in 2025,” he added.

The Justice Department sued to halt UnitedHealth’s acquisition of Change Healthcare (NASDAQ:CHNG) in February 2022, but the transaction was completed later that year.

This post appeared first on investing.com

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.






    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Editor's Pick

    Former president Donald Trump and his allies have filed hundreds of lawsuits, with more to come, seeking to tighten voting rules or disqualify voters....

    Economy

    LONDON (Reuters) – Bank of England interest rate-setter Megan Greene said she still believed the central bank should take a cautious approach to cutting...

    Editor's Pick

    Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

    Latest News

    Warner Bros. Discovery said Thursday its streaming platform Max added 7.2 million global subscribers in the third quarter. It marked the biggest quarterly growth for...

    Disclaimer: beneficialinvestmentnow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 beneficialinvestmentnow.com